comparemela.com

Latest Breaking News On - Alter pharma group - Page 4 : comparemela.com

Investegate |Hyloris Pharmaceuticals SA Announcements | Hyloris Pharmaceuticals SA: Correcting -- Hyloris reports results for the full year 2021

Milla Pharmaceuticals : Announces Approval and Launch of a Generic Version of Sodium Acetate Injection 2MEQ/mL by Pfizer Inc

Milla Pharmaceuticals : Announces Approval and Launch of a Generic Version of Sodium Acetate Injection 2MEQ/mL by Pfizer Inc
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Milla Pharmaceuticals Announces Approval and Launch of a Generic Version of Sodium Acetate Injection 2MEQ/mL by Pfizer Inc - Press Release

Milla Pharmaceuticals Announces Approval and Launch of a Generic Version of Sodium Acetate Injection 2MEQ/mL by Pfizer Inc - Press Release
wiredprnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wiredprnews.com Daily Mail and Mail on Sunday newspapers.

Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead Hyloris Pharmaceuticals SAAugust 4, 2021 GMT  On target to grow the broad product pipeline with at least 3 additional programmes before end 2021 Significant expansion of commercial footprint of non-opioid pain treatment Maxigesic® IV Expected to start 2 clinical studies and to report the results from 2 clinical studies before year-end €53.47 million in cash and cash equivalents to execute ambitious growth strategy Conference call and webcast today at 3pm CEST/9am EST (details below) Liège, Belgium – 4 August 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today reports its condensed consolidated financial results for the six-month period ending 30 June 2021,

Hyloris Pharmaceuticals SA: Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter Pharma Group

Hyloris Pharmaceuticals SA: Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter Pharma Group
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.